http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2413717-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_45f22389190af7c96c1788d21521588d |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4418 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4035 |
| filingDate | 2009-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c66cc73795dec621e2184ce46522751 |
| publicationDate | 2011-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2413717-C2 |
| titleOfInvention | Anti-hypertension organic salt |
| abstract | FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to field of organic chemistry and pharmaceutics and deals with novel anti-hypertension salt of general formula [(R1-COO-)(H3N-R2)], where R1 is inhibitor of angiotensin-converting enzyme, selected from group, which consists of perindoprilat, ramiprilat, spiraprilat, benazeprilat, moexiprilat, trandalaprilat, fosinoprilat, enalaprilat, zofenoprilat or lisinopril, and R2 -calcium channel blocker, selected from group, consisting of amlodipine, lacidipine, felodipine, isradipine. ^ EFFECT: invention ensures reduction of therapeutic doses and side effects. ^ 3 dwg, 2 tbl, 3 ex |
| priorityDate | 2008-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 116.